Trending...
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- Levata Acquires Logiscenter to Accelerate Growth in Enterprise IT and Data Capture Solutions
CHICAGO, June 22, 2025 ~ A recent study has revealed that oral semaglutide, a medication used to treat type 2 diabetes, can significantly reduce the risk of cardiovascular events by 14%. The results were presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago as a late-breaking symposium.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- Chicago: Mayor Johnson, City Officials Honor 1995 Heat Wave Victims, Forgotten WWII Hero Emilio Aguirre with Full Military Funeral Honors
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
Filed Under: Business
0 Comments
Latest on illi News
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- AI Maturity Emerges as Key Driver of ROI, New Protiviti Study Finds
- Premier Custom Hardwood Flooring Launches New Website to Better Serve Homeowners and Businesses in the NW Chicago Suburbs
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- WIOA-Funded Seats Still Available for Summer Product-Owner Training
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Entyre Solutions Launches to Support Senior Living Operators
- Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio USA - English USA - English USA - Français Japan - Japanese USA - Deutsch
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
- Naperville Police Initiate Death Investigation
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Mayor Johnson Appoints Era Patterson As Executive Director Of The Chicago Office Of Public Safety Administration